Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews
Tóm tắt
Từ khóa
Tài liệu tham khảo
Wiersma D, 1998, Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort, Schizophr Bull, 24, 75, 10.1093/oxfordjournals.schbul.a033315
Barnes TRE, 2003, Treatment-resistant schizophrenia, 2, 489
Altamura AC, 2005, Some biological correlates of drug resistance in schizophrenia: a multidimensional approach, World J Biol Psychiatry, 6, 23, 10.1080/15622970510030027
Meltzer HY, 1997, Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance, Am J Psychiatry, 154, 475, 10.1176/ajp.154.4.475
Henna J, 1999, Predictors of response and outcome in treatment resistant versus non treatment resistant schizophrenic patients, Schizophrenia Research, 36, 281
2002
Brenner HD, 1990, Defining treatment refractoriness in schizophrenia, Schizophr Bull, 16, 551, 10.1093/schbul/16.4.551
Kane J, 1988, Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine, Arch Gen Psychiatry, 45, 789, 10.1001/archpsyc.1988.01800330013001
El-Sayeh HG, 2006, Aripiprazole for schizophrenia, Cochrane Database Syst Rev, CD004578
Bhattacharjee J, 2008, Aripiprazole versus typical antipsychotic drugs for schizophrenia, Cochrane Database Syst Rev, CD006617
Nussbaum AM, 2008, Paliperidone for schizophrenia, Cochrane Database Syst Rev, CD006369
Srisurapanont M, 2004, Quetiapine for schizophrenia, Cochrane Database Syst Rev, CD000967
Hunter RH, 2003, Risperidone versus typical antipsychotic medication for schizophrenia, Cochrane Database Syst Rev, CD000440
Gilbody SM, 2000, Risperidone versus other atypical antipsychotic medication for schizophrenia, Cochrane Database Syst Rev, CD002306
Jayaram MB, 2006, Risperidone versus olanzapine for schizophrenia, Cochrane Database Syst Rev, CD005237
Moher D, 2008, When and how to update systematic reviews, Cochrane Database Syst Rev, MR000023
Carson WH, 2002
Kane J, 2003
Daniel DG, 2004
Oren D, 2005
Carson WH, 2000
Carson WH, 2000, Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo, European Neuropsychopharmacology, 10, S309, 10.1016/S0924-977X(00)80358-2
Csernansky JG, 2003, Treatment of schizophrenia: preventing the progression of disease, Psychiatr Clin North Am, 26, 367, 10.1016/S0193-953X(02)00113-2
Daniel DG, 2000, Aripiprazole, a novel antipsychotic: overview of a phase II study result, International Journal of Neuropsychopharmacology, 3
Kujawa M, 2002, Aripiprazole for long-term maintenance treatment of schizophrenia, International Journal of Neuropsychopharmacology, 5
Chang JS, 2008, Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial, J Clin Psychiatry, 69, 720, 10.4088/JCP.v69n0505
Kane JM, 2007, Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine, J Clin Psychiatry, 68, 213, 10.4088/JCP.v68n0206
Davidson M, 2007, Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study, Schizophr Res, 93, 117, 10.1016/j.schres.2007.03.003
Kramer M, 2007, Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study, J Clin Psychopharmacol, 27, 6, 10.1097/JCP.0b013e31802dda4a
Marder SR, 2007, Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study, Biol Psychiatry, 62, 1363, 10.1016/j.biopsych.2007.01.017
Tzimos A, 2006
Turkoz I, 2008, Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia, Neuropsychiatr Dis Treat, 4, 949
Canuso CM, 2009, Randomized, double-blind, placebo-controlled study of paliperidone extended-release quetiapine in inpatients with recently exacerbated schizophrenia, Am J Psychiatry, 166, 691, 10.1176/appi.ajp.2009.08040613
Hirsch S, 1994, A multicentre, double-blind, placebo-controlled comparison of low and high dosage regimens of SeroquelTM in the treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia, European Neuropsychopharmacology, 4, 384, 10.1016/0924-977X(94)90211-9
Link CGG, 1995, 'Seroquel' treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia: A multicentre, placebo-controlled, double-blind comparison of low and high dosage regimens, European Neuropsychopharmacology, 5, 346
Small JG, 1997, Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo. Seroquel Study Group, Arch Gen Psychiatry, 54, 549, 10.1001/archpsyc.1997.01830180067009
Addington DE, 1996
Arvanitis LA, 1996, 'Seroquel' (ICI 204,636): an atypical antipsychotic: results from a multiple fixed dose, placebo-controlled study, European Neuropsychopharmacology, 6, 10.1016/0924-977X(96)87987-9
Arvanitis LA, 1996
Arvanitis LA, 1997
Arvanitis LA, 1997, Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group, Biol Psychiatry, 42, 233, 10.1016/S0006-3223(97)00190-X
Arvanitis LA, 1966, ICI 204,636, an atypical antipsychotic: results from a multiple fixed-dose, placebo-controlled trial, Psychopharmacology Bulletin, 32
Borison RL, 1996, A comparison of five fixed doses of 'seroquel' (ICI 204,636) with haloperidol and placebo in patients with schizophrenia, Schizophrenia Research, 18, 10.1016/0920-9964(96)85441-7
Borison RL, 1996, A multiple fixed-dose, placebo-controlled trial with 'seroquel': An atypical antipsychotic, Biological Psychiatry, 39, 597, 10.1016/0006-3223(96)84278-8
Cantillon M, 1998
Cantillon M, 1998
Cantillon M, 1998
Hong WW, 1996, 'Seroquel' (ICI 204,636): not different from placebo for EPS or prolactin, Biological Psychiatry, 39
Hong WW, 1996, 'Seroquel' (ICI 204-636) does not differ from placebo in the incidence of EPS or effect on plasma prolactin, European Neuropsychopharmacology, 6
Hong WW, 1996
Hong WW, 1995
Fabre LF, 1995, ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia, Clin Ther, 17, 366, 10.1016/0149-2918(95)80102-2
Borison RL, 1996, ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia, J Clin Psychopharmacol, 16, 158, 10.1097/00004714-199604000-00008
Arvanitis L, 1994, A multicentre, placebo-controlled double-blind evaluation of SeroquelTM in hospitalised patients with acute exacerbation of chronic and subchronic schizophrenia, European Neuropsychopharmacology, 4, 10.1016/0924-977X(94)90213-5
Link CGG, 1995, SeroquelTM treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia: A multicentre, placebo-controlled, double-blind comparison of low and high dosage regimens, European Neuropsychopharmacology, 5, 346
Barzega G, 1999, Efficacia e tollerabilita dell' antipsychotico atipico quetiapina: uno studio in doppio cieco, Minerva Psichiatrica, 40, 297
Barzega G, 2000, Quetiapine in schizophrenic patients: a high- and low-dose double-blind comparison, European Journal of Psychiatry, 14, 221
Fleischhacker WW, 1995
King DJ, 1996, 'Seroquel' (ICI 204636): an atypical antipsychotic - results from Phase III, European Neuropsychopharmacology, 6
King DJ, 1996
King DJ, 1998, A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia, Psychopharmacology (Berl), 137, 139, 10.1007/s002130050603
Reuther E, 1996, Results of a multicenter study comparing the dosage and the dosage regimen of ICI 204,636 ('Seroquel'), Nervenarzt, 67
Purdon SE, 2000, Long-term treatment of quetiapine improves cognitive function in schizophrenia, Biological Psychiatry, 47, 10.1016/S0006-3223(00)00402-9
Purdon SE, 2001, Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol, J Psychiatry Neurosci, 26, 137
Copolov DL, 2000, A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia, Psychol Med, 30, 95, 10.1017/S0033291799001476
Fleishhacker W, 1996, ICI 204,636 (Seroquel): a putative new antipsychotic: results from Phase III trials, Schizophrenia Research, 18
Hellewell JSE, 1996, Switching from a conventional antipsychotic (haloperidol) to an atypical antipsychotic ('Seroquel'-ICI 204,636), European Neuropsychopharmacology, 6
Link C, 1996
Empfield JR
Link C, 1994, A multicentre, double-blind, controlled comparison of SeroquelTM and chlorpromazine in the treatment of hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia, European Neuropsychopharmacology, 4, 10.1016/0924-977X(94)90212-7
Peuskens J, 1997, A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia, Acta Psychiatr Scand, 96, 265, 10.1111/j.1600-0447.1997.tb10162.x
Buckley PF, 2001
Emsley RA, 1999
Emsley RA, 2001, Treatment of depressive symptoms in partially refractory schizophrenia: efficacy of quetiapine versus haloperidol, European Neuropsychopharmacology, 11, 10.1016/S0924-977X(01)80319-9
Emsley RA, 1999, Efficacy and tolerability of 'Seroquel' compared with haloperidol in schizophrenic patients partially responsive to conventional antipsychotic treatment, European Neuropsychopharmacology, 9, 10.1016/S0924-977X(99)80283-1
Emsley RA, 2000, A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment: PRIZE Study Group, Int Clin Psychopharmacol, 15, 121, 10.1097/00004850-200015030-00001
Emsley RA, 2000, Efficacy of seroquel in treating all of the positive and negative symptoms of schizophrenia, Schizofrenia Research, 41
Goldstein JM, 2000
Nasrallah HA, 2001, Patterns of response in patients with schizophrenia partially responsive to fluphenazine and switched to quetiapine or haloperidol, European Neuropsychopharmacology, 11, 10.1016/S0924-977X(01)80314-X
Weiden PJ, 2001, Switching from fluphenazine to quetiapine ameliorates extrapyramidal symptoms and neuroendocrine side effects in patients with schizophrenia, European Neuropsychopharmacology, 11, S262, 10.1016/S0924-977X(01)80315-1
Kudo Y, 2000, Clinical evaluation of quetiapine fumarate for the treatment of schizophrenia: a double-blind controlled study using mosapramine hydrochloride as a control, Rinsyo Iyaku, 16, 1807
Kudo Y, 1999
Mullen J, 2001, A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study, Clin Ther., 23, 1839, 10.1016/S0149-2918(00)89080-3
Tandon R, 2001
Conley RR, 2005, Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia, Clin Neuropharmacol, 28, 163, 10.1097/01.wnf.0000172993.89879.0f
Genç Y, 2007, Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study, Adv Ther, 24, 1, 10.1007/BF02849987
Blin O, 1996, Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients, J Clin Psychopharmacol, 16, 38, 10.1097/00004714-199602000-00007
Chouinard G, 1993, A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients, J Clin Psychopharmacol, 13, 25, 10.1097/00004714-199302000-00004
Claus A, 1992, Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparitive study, Acta Psychiatr Scand, 85, 295, 10.1111/j.1600-0447.1992.tb01473.x
Hoyberg OJ, 1993, Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations, Acta Psychiatr Scand, 88, 395, 10.1111/j.1600-0447.1993.tb03480.x
Huttunen MO, 1995, Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial, Acta Psychiatr Scand, 91, 271, 10.1111/j.1600-0447.1995.tb09781.x
Marder SR, 1994, Risperidone in the treatment of schizophrenia, Am J Psychiatry, 151, 825, 10.1176/ajp.151.6.825
Min SK, 1993, Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial, Yonsei Med J, 34, 179, 10.3349/ymj.1993.34.2.179
Peuskens J, 1995, Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group, Br J Psychiatry, 166, 712, 10.1192/bjp.166.6.712
Potkin SG, 1997
Bouchard RH, 1998
Mahmoud RA, 1998
Namjoshi M, 2002
Namjoshi M, 2002, Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a U.S. randomized controlled trial, Eur Neuropsychopharmacol, 10.1016/S0924-977X(02)80471-0
Conley RR, 2001, A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder, Am J Psychiatry, 158, 765, 10.1176/appi.ajp.158.5.765
Jeste DV, 2003, International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia, Am J Geriatr Psychiatry, 11, 638, 10.1097/00019442-200311000-00008
Tran PV, 1997, Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders, J Clin Psychopharmacol, 17, 407, 10.1097/00004714-199710000-00010
Lieberman JA, 2005, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, N Engl J Med, 353, 1209, 10.1056/NEJMoa051688
Keefe RS, 2006, One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia, Schizophr Res, 81, 1, 10.1016/j.schres.2005.07.038
Purdon SE, 2000, Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol: The Canadian Collaborative Group for research in schizophrenia, Arch Gen Psychiatry, 57, 249, 10.1001/archpsyc.57.3.249
Casey DE, 2003, Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia, Neuropsychopharmacology, 28, 182, 10.1038/sj.npp.1300023
Hosalli P, 2003, Depot risperidone for schizophrenia, Cochrane Database Syst Rev, CD004161
Kane JM, 2003, Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic, Am J Psychiatry, 160, 1125, 10.1176/appi.ajp.160.6.1125
Suzuki T, 2008, Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone, Hum Psychopharmacol, 23, 455, 10.1002/hup.959
Freudenreich O, 2007, Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial, Schizophr Res, 92, 90, 10.1016/j.schres.2006.12.030
Lewis SW, 2006, Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia, Schizophr Bull, 32, 715, 10.1093/schbul/sbj067
Honer WG, 2006, Clozapine alone versus clozapine and risperidone with refractory schizophrenia, N Engl J Med, 354, 472, 10.1056/NEJMoa053222
Leucht S, 2009, A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia, Am J Psychiatry, 166, 152, 10.1176/appi.ajp.2008.08030368
Rosa MA, 2005, Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia, Rev Bras Psiquiatr, 27, 178, 10.1590/S1516-44462005000300005
Kahn RS, 2008, Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial, Lancet, 371, 1085, 10.1016/S0140-6736(08)60486-9